Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study

Robert Benamouzig, Mourad Benallaoua, Jean-Christophe Saurin, Marouane Boubaya, Christophe Cellier, René Laugier, Magalie Vincent, Christian Boustière, Rodica Gincul, Elia Samaha, Philippe Grandval, Thomas Aparicio, Gheorghe Airinei, Bakhtiar Bejou, Cyriaque Bon, Jean-Jacques Raynaud, Vincent Levy and Denis Sautereau

Abstract

Background: Gastrointestinal angiodysplasias (GIADs) could be responsible for recurrent bleeding and severe anemia. Somatostatin analogs could reduce transfusion requirements in these patients but no randomized controlled study is available. The main objective of the ANGIOPAS phase II double-blinded randomized, noncomparative study was to assess the effectiveness of pasireotide-LAR in reducing transfusion requirements in patients with refractory GIADs bleeding.

Methods: A total of 22 patients with transfusion requirements ≥6 units of packed red blood cells (pRBCs) during the 6 months prior to inclusion were randomized to receive pasireotide-LAR 60 mg (n = 10) or placebo (n = 12) every 28 days for 6 months. Patients were then followed for an additional 6 months after stopping treatment.

Results: The pasireotide-LAR and placebo groups were equivalent for age, sex, comorbidities and transfusion requirement during the reference period (median 13 and 9.5 pRBCs). A 50 and 83% success rate (success defined as a decrease of at least 30% of transfused pRBCs) was observed in the pasireotide-LAR arm in the Intent to Treat (ITT) and per protocol (PP) analysis respectively. The need for transfusion during the intervention period was 3 pRBC units in the pasireotide-LAR group (range 0–26) and 11.5 pRBC units in the placebo group (range 0–23). Overall, three cases with glycemic control impairment were observed in the pasireotide-LAR group including one de novo diabetes.

Conclusion: This double-blinded noncomparative randomized phase II study suggests, for the first time, the effectiveness of pasireotide-LAR 60 mg every 28 days to decrease the transfusion requirement in patients with recurrent bleeding due to GIADs.

Keywords: angiodysplasia, GIADs bleeding, somatostatin analog
failure, liver cirrhosis, aortic stenosis, left ventricular assist devices and von Willebrand’s disease.

GIADs may be responsible for occult or overt gastrointestinal bleeding. Despite frequent spontaneous bleeding stops, GIADs rebleeding is frequent. GIADs may require transfusion or endoscopic therapies using argon plasma coagulation or other techniques. In 20–40% of cases, GIADs rebleeding is observed despite optimal endoscopic therapy. In these situations, medical therapies are proposed. Hormonal therapy with estrogens and progesterone introduced in the 1950s are no longer used as they appear inefficient in a well conducted case-control study and a randomized study. Thalidomide 100 mg daily was reported to be useful in a series of patients and further proven to be efficient in a randomized study including relatively young patients. However, thalidomide’s frequent side effects limit its long-term use, especially in older patients. Few cases of patients with GIADs bleeding were recently treated with bevacizumab.

Several observational studies and a meta-analysis consistently suggested that somatostatin analogs could reduce rebleeding and transfusion requirements in patients with GIADs bleeding refractory or inaccessible to endoscopic therapies (Table 1). However, the studies testing various therapeutic schedules used an inadequate design and failed to demonstrate this putative benefit. Indeed, no randomized study has properly evaluated somatostatin analogs in patients with GIADs bleeding refractory to endoscopic therapies.

Pasireotide-LAR is a new long-acting analog of somatostatin. Like the natural somatostatin and other somatostatin analogs, pasireotide exerts its pharmacological activity via binding to the five somatostatin receptors subtypes. Pasireotide binds with high affinity to four of the five receptors with a specific 40-fold increased affinity to subtype five compared with other analogs. Pasireotide-LAR is mainly used for acromegaly and Cushing’s disease. The main objective of the ANGIOPAS study was to assess the effectiveness of pasireotide-LAR in reducing transfusion requirements in patients with GIADs recurrent bleeding refractory to endoscopic therapy.

Patients and methods

Study design
The ANGIOPAS study is a multicenter prospective double-blinded randomized noncomparative phase II study designed to evaluate the pasireotide-LAR interest in the control of GIADs refractory rebleeding. The study was divided into three periods: (1) preinclusion or basal period up to 6 months before randomization allowing the prospective selection of refractory GIADs patients with transfusion requirement ≥6 units of pRBCs; (2) 6 months intervention period corresponding to the treatment period with intramuscular injection of pasireotide-LAR 60 mg or placebo every 28 days according to a 1:1 randomization and (3) follow-up period up to 6 months (Figure 1). The placebo consists of the same vehicle without the active drug (similar aspect and conditioning). The placebo was fabricated in the same facility as the tested drug. Both patients and investigators were blinded during the study. In case of active bleeding during the follow-up period, the patients could be treated with pasireotide-LAR in an unblinded manner. During intervention and follow-up periods, patients had monthly monitoring. At each visit, physical examination was performed and the following parameters were collected: age, weight, blood pressure, Karnofsky index, number of the pRBC units transfused, number of days of hospitalization for bleeding, endoscopic procedures, iron treatment. Blood sampling was performed monthly for hemoglobin, coagulation measurement, glycemia and liver function tests. Adverse events were collected at each visit. Electronic randomization and treatment allocation were performed by a central unit (CREAPHARM, Le Haillan, France). The ANGIOPAS study was performed according to the French and European regulations. The study protocol has been recorded on clinicalTrials.gov and European Clinical Trials web site under NCT02622906 and 2011-002579-40 number respectively. The ANGIOPAS study was approved by the Human Studies Committee at coordinator center PC/AP 31-2011. The permission for the study was obtained from Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) under the number AEC/A110808-42. This study was also approved by the Commission Nationale de l’Information et des Libertés (CNIL).
Table 1. Series and case-control studies evaluating somatostatin analogs effect in patients with GIADs rebleeding.

| Author                        | Country, year | Number of patients | Treatment daily dose | Comparator | Follow up, months | Primary outcome               | Effect          |
|-------------------------------|---------------|--------------------|----------------------|------------|------------------|------------------------------|----------------|
| Torsoli and colleagues        | Italy 1991    | 1                  | Octreotide 50 µg × 2/day | Pretreatment | 18               | Hb level Bleeding            | Effective       |
| Rossini and colleagues        | Italy 1993    | 3                  | Octreotide 100 µg × 2/day | Pretreatment | 10–40            | Hb level Bleeding Transfusions | Effective (2/3) |
| Andersen and Aaseby           | Denmark 1996  | 1                  | Octreotide 100 µg × 2/day | Pretreatment | 26               | Hb level Bleeding            | Effective       |
| Nardone and colleagues        | Italy 1999    | 17                 | Octreotide 100 µg × 3/day | Pretreatment | 6                | Hb level Bleeding Transfusions | Effective (10/17) |
| Bowers and colleagues         | Ireland 2000  | 2                  | Octreotide 100–300 µg × 2/day | Pretreatment | 4 and 21        | Hb level Bleeding Transfusions | Effective       |
| Orsi and colleagues           | Italy 2001    | 3                  | Octreotide-LAR 20 mg/month | Pretreatment | 15–17            | Bleeding Transfusions        | Effective       |
| Nordquist and Wallach         | USA 2002      | 1                  | Octreotide 50 µg/h       | Pretreatment | 4                | Bleeding Transfusions        | Effective       |
| Coppola and colleagues        | Italy 2002    | 1                  | Octreotide 100 µg × 3/day | Pretreatment | 3                | Bleeding Transfusions        | Not effective   |
| Blich and colleagues          | Israel 2003   | 1                  | Octreotide 100 µg/every 2 days | Pretreatment | 28               | Hb level Bleeding Transfusions | Effective       |
| Rivera and colleagues         | Spain 2005    | 2                  | Octreotide 100 µg/day    | Pretreatment | 7 and 24        | Bleeding Transfusions        | Effective       |
| Junquera and colleagues       | Spain 2007    | 30                 | Octreotide 50–100 µg × 2/day | Parallel unbalanced control group | 13 [12–24] | Bleeding Transfusions | Effective [25/30 versus 17/35] |
| Scaglione and colleagues      | Italy 2007    | 13                 | OCT-LAR 10 mg/month     | Pretreatment | 33 [12–60]      | Hb level Bleeding Transfusions | Effective (9/13) |
| Boesby and colleagues         | Denmark 2008  | 1                  | Octreotide 4 months then Octreotide-LAR | Pretreatment | 4                | Bleeding Transfusions        | Effective       |
| Almadi and colleagues         | Canada 2009   | 3                  | Octreotide 100 µg × 2/day then octreotide-LAR 10–20 mg/month | Pretreatment | 12               | Bleeding Transfusions        | Effective (2/3) |
| Molina Infante and colleagues | Spain 2009    | 11                 | Octreotide-LAR 20 mg/month | Pretreatment | 15 [5–48]       | Transfusions                 | Effective [2/11] |
| Bon and colleagues            | France 2012   | 15                 | Octreotide-LAR 20 mg/month Lanreotide 90 mg/28 days | Pretreatment | 12 [6–36]       | Hb level Bleeding Transfusions | Effective       |

(Continued)
Patient selection
All patients with uncontrolled occult or overt bleeding due to GIADs refractory or inaccessible to endoscopic therapies with transfusion requirement ≥6 units of pRBCs from six tertiary hospital centers were considered for inclusion. Other inclusion criteria were age >18 years, presence of GIADs confirmed by endoscopy, failure or impossible endoscopic therapy, affiliation to the French national social security insurance and signed informed consent. Exclusion criteria were hereditary hemorrhagic telangiectasia, previous treatment with somatostatin analog during the 6 months prior to inclusion, symptomatic cholelithiasis, uncontrolled diabetes [glycated hemoglobin (HbA1c) >8%], previous bleeding from esophageal varices, aspartame amino-transferase (ASAT) or alanine amino-transferase (ALAT) > upper limit of normal (ULN) or total bilirubin > 1.5 ULN, prothrombin (TP) < 50%, platelets < 75,000/mm³, activated partial thromboplastin time (aPTT) > 1.5-times the control, QTcF > 450 ms, history of syncope, history of ventricular tachycardia or fibrillation, familial history of idiopathic sudden death, myocardial infarction within 6 months, congestive heart failure grade III and New York Heart Association, metastatic malignancy and impossible follow up.
for psychological or geographical reasons. Patients with antivitamin K therapies were allowed to participate using cautious deep subcutaneous injection. Pregnant or nursing women, women and men of reproductive age without effective contraception and women of childbearing age who have not carried out a pregnancy test were not allowed to participate.

Criteria of evaluation
The main evaluated outcome was the evolution in transfusion requirement during the 6 months treatment and follow-up periods. These time periods were selected according to available data from observational studies suggesting that a preventive effect could be demonstrated when such a period is considered. For the analysis of this primary endpoint, success was arbitrarily defined as a minimum 30% reduction in the number of transfused pRBCs between the 6-month period prior to randomization and 6 months after randomization. A 30% decrease in transfusion requirement was arbitrarily selected according to expected effect from observational studies. This quantity of effect was also considered since such a decrease could convince of the real interest of this therapy. Pasireotide-LAR was arbitrary classified as of no or futile interest for a proportion of success <15% and of interest for future phase III studies for a proportion of success ≥40%. The secondary outcomes were the evolution in the number of transfused pRBCs, the number of patients requiring transfusion, the number of endoscopic procedures and the number and days of hospitalization. Assessment of toxicity was performed during monthly visits including physical examination and blood testing.

Statistical analysis
Patient data were compared between basal and treatment period for each arm. A one-stage Fleming–A’Hern design was used to evaluate the probability that $p < p_0$ and $p > p_1$ where $p$ is the observed proportion of success, $p_0$, chosen as 15%, was the maximal expected proportion of success for a drug with no or futile effectiveness and $p_1$, chosen as 40%, was the minimal expected proportion of success for a truly effective drug requiring future phase III studies. According to these hypotheses, the number needed to be included in the treated group was calculated to be 22 for a 0.05 $\alpha$ bilateral risk and a 0.80 $\beta$ risk.
If at least 7 out of 22 patients meet the response criteria, pasireotide-LAR will be considered effective. The recruitment of a control placebo group of 22 patients was also planned to better describe the natural history of these patients and reduce patient selection bias. As stated previously, no statistical comparison was originally scheduled between the two arms in this noncomparative phase II study. So the study size was not calculated to demonstrate a difference between the pasireotide-LAR and placebo groups.

The primary analysis was performed by Intent to Treat (ITT) for all randomized patients regardless whether treatment was received or not. In the ITT analysis, the worst possible value for the primary endpoint was attributed to missing data. So a case with incomplete treatment in the treated arm was classified as failure whatever the observed result. Whereas, a case in the placebo group with incomplete treatment was classified as a success, whatever the observed result. In addition, an explanatory per protocol (PP) analysis of all patients randomized who received all planned injections and treated without other violation or major deviation from protocol was performed.

Wilcoxon’s test was performed to compare the transfusion requirement between the reference period and intervention period for each arm. The 95% confidence intervals (CIs) were calculated. A $p$-value < 0.05 was considered statistically significant. Analyses were carried out using R statistical software version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria, http://www.r-project.org). All authors had access to the study data and reviewed and approved the final manuscript.

### Results

**Recruitment**

From March 2012 to December 2013, 25 consecutive eligible patients from six tertiary hospital centers were considered for inclusion. A total of 22 patients (16 men and 6 women) were randomized, 10 in the pasireotide-LAR group and 12 in the placebo group (Figure 2). The planned additional 6 months of follow up without treatment was complete in four patients in the pasireotide-LAR group and in four in the placebo group. The pasireotide-LAR and placebo groups were equivalent for age (mean 70 ± 8 and 72 ± 16 years respectively), sex (7 and 9 men), weight (73 ± 15 and 72 ± 14 kg), transfusion requirements during the reference basal period (median 13 and 9.5 pRBCs) and hemoglobin at baseline (mean 9.6 ± 1.2 and 9.2 ± 1.9 g/dl) (Table 2). The median duration of bleeding before randomization was 36 months (range 3–192). Melena and rectal bleeding were observed at inclusion in nine and four cases respectively. All patients had at least an upper endoscopy, a colonoscopy and a small bowel capsule endoscopy. Enteroscopy with argon plasma coagulation was performed before inclusion in 21 cases (1–5 sessions). All patients had multiple GIADs. The most frequent GIAD localization was the small bowel ($n = 21$), then the proximal colon ($n = 11$) and the stomach ($n = 7$). A total of 12 patients out of the 22 (55%) had multiple GIADs localization. Comorbidities including ischemic disease requiring or not stenting and valvulopathy with or without valve replacement were frequent in both groups (Table 2). Concomitant medication with anticoagulants or antiplatelet agents was present at inclusion in 13 cases (60%) (Table 2).

**Primary endpoint**

**Pasireotide-LAR group.** In the ITT primary analysis, according to the method of the worst situation, four patients who did not receive the full 6 months of the scheduled intervention were arbitrarily classified as failures regardless of the evolution in transfusion requirement. With this restrictive method, success was characterized in 5 out of the 10 patients (50%; 95% CI 19–81%) in the pasireotide-LAR group. In the PP analysis, without this restrictive analysis, the success rate was 83% (95% CI 36–99%) (Table 3).

Overall, two patients from the placebo group with persistent bleeding after the placebo 6 months treatment were treated with pasireotide-LAR in an unblinded manner. According to the analysis of these 12 patients (10 patients of the pasireotide-LAR group and 2 patients of the placebo group) treated with pasireotide-LAR, the ITT success rate was 58% (95% CI 28–85%) and the PP success rate was 88% (95% CI 47–99%).

Suspension of the pasireotide-LAR 6 months treatment in two patients from the pasireotide-LAR group with no further bleeding during
treatment was followed by renewed bleeding. In one of these two cases, resumption of pasireotide-LAR led to a further bleeding stop.

**Placebo group.** Mirroring and using the described worst case method, 4 patients out of the 12 in the placebo group who did not receive the full 6 months of placebo were arbitrarily classified as successes regardless of the evolution in transfusion requirement. Then, ITT success rate in the placebo arm was 50% (95% CI 21–79%). This rate is the same as in the pasireotide arm according to the method of the worst situation yet presented. When this artificial method was not used, the observed PP success rate was 25% (95% CI 3–65%).

**Secondary endpoints**
The median number of transfused pRBC units during the treatment period was 3 (range 0–26) in the pasireotide-LAR group and 11.5 (range 0–23) in the placebo group. The evolution of

---

**Table 2. Demographic data.**

| Demographic data | Pasireotide-LAR (n = 10) | Placebo (n = 12) |
|------------------|-------------------------|-----------------|
| **Sex [%]**      | 7 male (70%) | 9 male (75%) |
| **Age [mean ± SD]** | 70.4 ± 8.2 | 72 ± 16.2 |
| **BMI [mean ± SD]** | 24.7 ± 4.6 | 26 ± 4.4 |
| **Blood pressure [systolic/diastolic, mean ± SD]** | 120 ± 64/78 ± 15 | 123 ± 8/69 ± 8 |
| **Hb level at inclusion [g/dl, mean ± SD]** | 9.6 ± 1.2 | 9.2 ± 1.9 |

| **Comorbidities** | |
|------------------|---|
| Arterial hypertension | 5 | 6 |
| Ischemic disease | 3 | 8 |
| Valvulopathy | 4 | 3 |
| Liver cirrhosis | 0 | 1 |
| Chronic renal failure | 1 | 0 |
| Diabetes | 5 | 2 |

| **Concomitant therapies** | |
|-----------------------------|---|
| Anticoagulants | 3 | 4 |
| Antiplatelet agents | 3 | 6 |
| Anticoagulants + antiplatelet agents | 1 | 2 |

| **GIADs bleeding** | |
|-------------------|---|
| GIADs mean number [range] | 5.7 ± 7.6 (1–26) | 2.4 ± 1.8 (1–6) |
| Number of pRBCs units during the basal period [mean ± SD, range] | 13.9 ± 7.9 (6–30) | 10 ± 4 (6–20) |

| **Angiodysplastic lesion localization** | |
|-----------------|---|
| Stomach [n] | 4 | 4 |
| Small bowel [n] | 6 | 6 |
| Colon [n] | 5 | 4 |

BMI, body mass index; Hb, hemoglobin; GIAD, gastrointestinal angiodysplasia; pRBC, packed red blood cell; SD, standard deviation.
Individual pRBC requirements is presented in Figure 3. The delta of pRBCs between the pasireotide-LAR treatment period and the reference period was $-67\%$ ($p = 0.035$). This delta was $+18\%$ in the placebo group ($p = 0.94$). Spontaneous stop bleeding was observed in two out of eight patients in the placebo group: 22 and 15 pRBC transfusion requirements during basal period versus 0 and 2 units during 6 months of follow up. No differences were observed in the proportion of patients requiring transfusion (67% in the pasireotide-LAR group and 75% in the placebo group), the proportion of patients requiring new endoscopy (17 and 25%) nor the proportion of patients requiring new hospitalization (83 and 63%). Exploratory analysis did not suggest any difference in these effects according to age ($>70$ or $>70$ years) nor to concomitant therapy with or without anticoagulant or antiplatelet (see Table 4).
Safety
Overall, two deaths occurred during the study: one in the placebo group and one in the treated group and considered unrelated to pasireotide (Table 5). This death occurred in a context of worsening condition in a patient with noninsulin-dependent diabetes, cardiomyopathy, chronic obstructive pulmonary disease, chronic liver disease and pulmonary hypertension. By the end of 2015, three additional deaths were observed, two in the placebo group and one in the pasireotide-LAR group which were considered unrelated to the treatment.

Overall, three cases with deterioration in glycemic control were observed in the pasireotide-LAR group including one with de novo diabetes requiring insulin therapy without need for PP treatment discontinuation. In addition, the diabetes treatment had to be adapted in a patient. Hypoglycemia associated with diarrhea was observed in one patient several days after the first pasireotide-LAR injection. This patient had a history of insulin-dependent diabetes, dyslipidemia, hypertension and peripheral arterial disease. After the onset of this adverse event, the investigator decided to stop the use of the product. The patient was monitored until complete disappearance of the adverse event few days later. A total of three cases of mild diarrhea were observed in the pasireotide-LAR group. Grade 1 transient nausea requiring no specific treatment was reported in one patient in the pasireotide-LAR group. No symptomatic biliary event was reported. No unexpected adverse events were observed during the study.

Discussion
Despite the use of a worst case scenario analysis, a 50% success rate in reducing the transfusion requirement was observed in the pasireotide-LAR arm ($n = 10$, ITT analysis). The success rate was arbitrarily defined as a decrease of more than 30% of transfusion requirements between the treated and the basal period in patients requiring at least 6 pRBC units during the last 6 months. We considered this threshold to be clinically relevant in such a population. In this ITT analysis, the worst possible value that is failure was attributed in case of true failure but also in case of incomplete follow

### Table 4. Exploratory analysis.

| Variable                          | Pasireotide-LAR | Placebo |
|----------------------------------|-----------------|---------|
| Age (year) ≥70                   | 2/4             | 3/4     |
| ITT, n/N                         | 2/4             | 3/8     |
| PP, n/N                          | 3/6             | 1/6     |
| Anticoagulant and/or antiplatelet | With With       | With Without |
| ITT, n/N                         | 1/3             | 2/4     |
| PP, n/N                          | 1/1             | 0/2     |

ITT, Intent to Treat; PP, per protocol.

### Table 5. Adverse events.

| Adverse events                  | Pasireotide-LAR | Placebo |
|---------------------------------|-----------------|---------|
| Death                           | 1               | 1       |
| Diarrhea                        | 4               | 0       |
| Nausea                          | 1               | 0       |
| Loss of appetite                | 1               | 0       |
| Hypoglycemia                    | 1               | 0       |
| Diabetes imbalance              | 4               | 2       |
| Gout                            | 1               | 0       |
| Heart failure                   | 1               | 0       |
| Kidney failure                  | 1               | 0       |
up, so this 50% success rate is a very conservative rate. Indeed, the success rate was 83% in the PP analysis of these 10 patients and 88% when all 12 pasireotide-LAR-treated patients were considered. As the PP success rate was lower in the placebo group and since patients had a long history of recurrent bleeding (median 36 months), we speculate that this effect was not due to spontaneous bleeding stop but to true pasireotide-LAR protection. This protective effect appears clearly in the changes in pRBC transfusion requirements between treatment and the reference period in the pasireotide-LAR arm (−67%).

These results are in line with previous observational data indicating a decrease in bleeding and pRBC transfusion requirements in patients treated with octreotide, octreotide-LAR or lanreotide.24–43 The quantity of effect observed in the ANGIOPAS study was in the range of these cases and in particular, of three series with significant transfusion requirements.39,40,43

We did not investigate the mechanism of action of pasireotide-LAR in this study. These putative mechanisms were described in an original paper45 and in recent in-depth reviews.46,47 The discussed mechanisms involved both physical factors with increased local tension and abnormal angiogenesis due to hypoxia as well as acquired hemostasis. In this study, the population was relatively old with cardiovascular comorbidities including ischemia and aortic valvular disease suggesting a putative role of ischemia. Patients were also frequently exposed to anticoagulants or antiplatelet agents, key contributing factors to rebleeding.

The main limitation of this study is its limited recruitment. The initial recruitment ANGIOPAS target has not been achieved. Only 25 patients were selected and 22 included despite 50 were initially considered. Several factors may explain this limited recruitment: scarcity of the pathology at the desired stage (refractory bleeding due to mesenteric infarction and transfusion requirement of more than 6 pRBC units during the last 6 months), exclusion criteria as QTcF > 450 ms which was frequently observed in these elderly patients with vascular comorbidities and the geographical remoteness of some patients that do not allow regular monitoring according to the protocol. This difficulty was also described by another team.41 Despite this limited recruitment and the restrictive attribution method for missing data, the observed success rates allow the rejection of a futile effect ($p < p_0$ hypothesis when $p_0 < 15\%$ with a 0.037 true error rate). Furthermore, the PP analysis of the patients exposed to pasireotide-LAR suggests the true effectiveness of pasireotide-LAR in reducing the transfusion requirement ($p \geq p_1$ hypothesis with $p_1 \geq 40\%$).

The balance between benefit and potential harm needs to be better evaluated in larger series but according to the refractory severe bleeding condition and fragile status of patients, a favorable balance is expected.

These results suggest effectiveness of pasireotide-LAR in the control of recurrent bleeding due to refractory GIADs. A multicenter collaborative network involving specialized centers will allow performing the needed phase III study to confirm these results.

Acknowledgements
This work was promoted by the SFED (Société Française d’Endoscopie Digestive) and was conducted by his scientific committee. We thank Dr Bisot-Locard for her full commitment in this study. This work is listed under ClinicalTrials.gov identifier: NCT02622906.

Funding
This research received funding from Novartis laboratory. Novartis laboratory did not participate in the elaboration of the study design, protocol or manuscript writing.

Conflict of interest statement
RB: Alfa Wassermann Pharma, Mayoly Spindler, Medtronic and Norgine.
MoB: None.
JCS: Abbvie, Bouchara, Intromedic, Mayoly Spindler, Medtronic, MSD and Recordati.
ChC: Abbvie, Aptalis, Gilead, MSD, Sciences Janssen and Vifor Pharma.
RL: Abbvie and Boston Scientific.
MV: None.
CB: Boston Scientific, Cousin Endosurg, Norgine and Olympus.
MaB: None.
RG: Ipsen Pharma.
ES: Amgen, Bayer, Ipsen Pharma, Novartis Oncology, Pierre Fabre, Pfizer, Roche, Sanofi and Vifor Pharma.
PG: Abbvie, Boston Scientific, Cook Medical, Mayoly Spindler and Takeda.
TA: Amgen, Novartis Oncology, Pfizer, Roche, Sanofi and Vifor Pharma.
GA: None.
BB: None.
CB: None.
JJR: None.
VL: Amgen, GSK, Mundi Pharma, Octa Pharma and Roche
DS: Boston Scientific.

References
1. Bollinger E, Raines D and Saitta P. Distribution of bleeding gastrointestinal angioectasias in a Western population. World J Gastroenterol 2012; 18: 6235–6239.
2. Sharma R and Gorbien MJ. Angiodysplasia and lower gastrointestinal tract bleeding in elderly patients. Arch Intern Med 1995; 155: 807–812.
3. Urgesi R, Cianci R, Pagliari D, et al. Is capsule endoscopy appropriate for elderly patients? The influence of ageing on findings and diagnostic yield: an Italian retrospective study. Dig Liver Dis 2015; 47: 1086–1088.
4. Scaglione G, Russo F, Franco MR, et al. Age and video capsule endoscopy in obscure gastrointestinal bleeding: a prospective study on hospitalized patients. Dig Dis Sci 2011; 56: 1188–1193.
5. Kalman RS and Pedrosa MC. Evidence-based review of gastrointestinal bleeding in the chronic kidney disease patient. Semin Dial 2015; 28: 68–74.
6. Igawa A, Oka S, Tanaka S, et al. Major predictors and management of small-bowel angioectasia. BMC Gastroenterol 2015; 15: 108.
7. Loscalzo J. From clinical observation to mechanism: Heyde’s syndrome. N Engl J Med 2012; 367: 1954–1956.
8. Suarez J, Patel CB, Felker GM, et al. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail 2011; 4: 779–784.
9. Franchini M and Mannucci PM. Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. Thromb Haemost 2014; 112: 427–431.
10. Richter JM, Christensen MR, Colditz GA, et al. Angiodysplasia. Natural history and efficacy of therapeutic interventions. Dig Dis Sci 1989; 34: 1542–1546.
11. Jackson CS and Gerson LB. Management of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 474–483; quiz 484.
12. Holleran G, Hall B, Zgaga L, et al. The natural history of small bowel angiodysplasia. Scand J Gastroenterol 2016; 51: 393–399.
13. Swanson E, Mahgoub A, MacDonald R, et al. Medical and endoscopic therapies for angiodysplasia and gastric antral vascular ectasia: a systematic review. Clin Gastroenterol Hepatol 2014; 12: 571–582.
14. May A, Friesing-Sosnik T, Manner H, et al. Long-term outcome after argon plasma coagulation of small-bowel lesions using double-balloon enteroscopy in patients with mid-gastrointestinal bleeding. Endoscopy 2011; 43: 759–765.
15. Lewis BS, Salomon P, Rivera-MacMurray S, et al. Does hormonal therapy have any benefit for bleeding angiodysplasia? J Clin Gastroenterol 1992; 15: 99–103.
16. Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001; 121: 1073–1079.
17. Hodgson H. Hormonal therapy for gastrointestinal angiodysplasia. Lancet Lond Engl 2002; 359: 1630–1631.
18. Szilagyi A and Ghali MP. Pharmacological therapy of vascular malformations of the gastrointestinal tract. Can J Gastroenterol 2006; 20: 171–178.
19. Ge ZZ, Chen HM, Gao YJ, et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011; 141: 1629–1637.e1–e4.
20. Garrido A, Sayago M, López J, et al. Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. Rev Esp Enferm Dig 2012; 104: 69–71.
21. Bauditz J. Effective treatment of gastrointestinal bleeding with thalidomide: chances and limitations. World J Gastroenterol 2016; 22: 3158–3164.
22. Marlu R, Barthelon J, Durand A, et al. Long-term therapy with bevacizumab in a patient with
Glanzmann’s thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesions. *Am J Gastroenterol* 2015; 110: 352–353.

23. Barré A, Dréanic J, Flaujac C, et al. Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann’s thrombasthenia? *Haemophilia* 2016; 22: e347–e348.

24. Torsoli A, Annibale B, Viscardi A, et al. Treatment of bleeding due to diffuse angiodysplasia of the small intestine with somatostatin analog. *Eur J Gastroenterol Hepatol* 1991; 3: 785–787.

25. Rossini FP, Arrigoni A and Pennazio M. Octreotide in the treatment of bleeding due to angiodysplasia of the small intestine. *Am J Gastroenterol* 1993; 88: 1424–1427.

26. Andersen MR and Aaseby J. Somatostatin therapy ameliorates chronic and refractory gastrointestinal bleeding caused by angiodysplasia. *Scand J Gastroenterol* 2003; 38: 801–803.

27. Nordone G, Rocco A, Balzano T, et al. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. *Aliment Pharmacol Ther* 1999; 13: 1429–1436.

28. Bowers M, McNulty O and Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia. *Scand J Gastroenterol* 1996; 31: 1037–1039.

29. Nardone G, Bon C, Aparicio T, Vincent M, et al. Octreotide in the treatment of angiodysplasia of the small intestine. *Br J Haematol* 2000; 108: 524–527.

30. Orsi P, Guatti-Zuliani C and Okolicsanyi L. Long-acting octreotide is effective in controlling rebleeding angiodysplasia of the gastrointestinal tract. *Dig Liver Dis* 2001; 33: 330–334.

31. Nordquist LT and Wallach PM. Octreotide for gastrointestinal bleeding of obscure origin in an anticoagulated patient. *Dig Dis Sci* 2002; 47: 1514–1515.

32. Blisch M, Fruchter O, Edelstein S, et al. Somatostatin therapy ameliorates chronic and refractory gastrointestinal bleeding caused by diffuse angiodysplasia in a patient on anticoagulation therapy. *Scand J Gastroenterol* 2003; 38: 801–803.

33. Rivera M, Lucero J, Guerrero A, et al. Octreotide in the treatment of angiodysplasia in patients with advanced chronic renal failure. *Nefrologia* 2005; 25: 332–335.

34. Junquera F, Sapers E, Videla S, et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. *Am J Gastroenterol* 2007; 102: 254–260.

35. Scaglione G, Pietrini L, Russo F, et al. Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. *Aliment Pharmacol Ther* 2007; 26: 935–942.

36. Boesby L, Christensen NJ and Kristensen LO. Somatostatin analogs in the treatment of bleeding GI-angiodysplasias. *Ugeskr Laeger* 2008; 170: 958.

37. Almadi M, Ghali PM, Constantine A, et al. Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review. *Can J Gastroenterol* 2009; 23: 625–631.

38. Molina Infante J, Pérez Gallardo B, Hernández Alonso M, et al. Octreotide long acting release for severe obscure gastrointestinal haemorrhage in elderly patients with serious comorbidities. *Med Clin* 2009; 133: 667–670.

39. Bon C, Aparicio T, Vincent M, et al. Long-acting somatostatin analogs decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia. *Aliment Pharmacol Ther* 2012; 36: 587–593.

40. Salgueiro P, Marcos-Pinto R, Liberal R, et al. Octreotide long-acting release is effective in preventing gastrointestinal bleeding due to angiodysplasias. *GE Port J Gastroenterol* 2014; 21: 176–183.

41. Nardone G, Compare D, Scarpignato C, et al. Long acting release-octreotide as “rescue” therapy to control angiodysplasia bleeding: a retrospective study of 98 cases. *Dig Liver Dis* 2014; 46: 688–694.

42. Ramos-Rosario HA, Badia Aranda E, Martin Lorente JL, et al. Efficacy of lanreotide in patients with gastrointestinal angiodysplasia refractory to octreotide therapy. *Gastroenterol Hepatol* 2016; 39: 213–214.

43. Holleran G, Hall B, Breslin N, et al. Long-acting somatostatin analogs provide significant beneficial effect in patients with refractory small bowel angiodysplasia: results from a proof of
concept open label mono-centre trial. *United Eur Gastroenterol* J 2016; 4: 70–76.

44. Brown C, Subramanian V, Wilcox CM, et al. Somatostatin analogs in the treatment of recurrent bleeding from gastrointestinal vascular malformations: an overview and systematic review of prospective observational studies. *Dig Dis Sci* 2010; 55: 2129–2134.

45. Junquera F, Saperas E, de Torres I, et al. Increased expression of angiogenic factors in human colonic angiodysplasia. *Am J Gastroenterol* 1999; 94: 1070–1076.

46. Dray X, Camus M, Coelho J, et al. Treatment of gastrointestinal angiodysplasia and unmet needs. *Dig Liver Dis* 2011; 43: 515–522.

47. Sami SS, Al-Araji SA and Ragunath K. Review article: gastrointestinal angiodysplasia—pathogenesis, diagnosis and management. *Aliment Pharmacol Ther* 2014; 39: 15–34.